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Comparing olive oil and C4-dietary oil, a
prodrug for the GPR119 agonist, 2-oleoyl
glycerol, less energy intake of the latter is
needed to stimulate incretin hormone
secretion in overweight subjects with type
2 diabetes
Mette Johannsen Mandøe1,2,3, Katrine Bagge Hansen1,2,3, Johanne Agerlin Windeløv1,2, Filip Krag Knop1,4,5,
Jens Frederik Rehfeld6, Mette Marie Rosenkilde 7, Jens Juul Holst1,2 and Harald Severin Hansen8
Abstract
Background/objective: After digestion, dietary triacylglycerol stimulates incretin release in humans, mainly through
generation of 2-monoacylglycerol, an agonist for the intestinal G protein-coupled receptor 119 (GPR119). Enhanced
incretin release may have beneﬁcial metabolic effects. However, dietary fat may promote weight gain and should
therefore be restricted in obesity. We designed C4-dietary oil (1,3-di-butyryl-2-oleoyl glycerol) as a 2-oleoyl glycerol (2-
OG)-generating fat type, which would stimulate incretin release to the same extent while providing less calories than
equimolar amounts of common triglycerides, e.g., olive oil.
Subjects and methods: We studied the effect over 180 min of (a) 19 g olive oil plus 200 g carrot, (b) 10.7 g C4 dietary
oil plus 200 g carrot and (c) 200 g carrot, respectively, on plasma responses of gut and pancreatic hormones in 13
overweight patients with type 2 diabetes (T2D). Theoretically, both oil meals result in formation of 7.7 g 2-OG during
digestion.
Results: Both olive oil and C4-dietary oil resulted in greater postprandial (P≤ 0.01) glucagon-like peptide 1 (GLP-1) and
glucose-dependent insulinotropic polypeptide (GIP) responses (incremental area under curve (iAUC)): iAUCGLP−1: 645 ±
194 and 702 ± 97 pM ×min; iAUCGIP: 4,338 ± 764 and 2,894 ± 601 pM ×min) compared to the carrot meal (iAUCGLP−1:
7 ± 103 pM ×min; iAUCGIP: 266 ± 234 pM ×min). iAUC for GLP-1 and GIP were similar for C4-dietary oil and olive oil,
although olive oil resulted in a higher peak value for GIP than C4-dietary oil.
Conclusion: C4-dietary oil enhanced secretion of GLP-1 and GIP to almost the same extent as olive oil, in spite of
liberation of both 2-OG and oleic acid, which also may stimulate incretin secretion, from olive oil. Thus, C4-dietary oil is
more effective as incretin releaser than olive oil per unit of energy and may be useful for dietary intervention.
Introduction
Weight loss is an important goal in the treatment of
obesity and diabetes, and can be achieved by a lower
intake of dietary fat as it is known that a higher dietary fat
intake is associated with weight gain.1 Furthermore, the
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drug orlistat,2 which decreases fat absorption, as well as
substitution of long-chain triglycerides with medium-
chain triglycerides in the diet3 are known to produce
weight loss in humans. In a human weight loss regime,
dietary fat restriction was, calorie for calorie, more efﬁ-
cient than carbohydrate restriction with respect to body
fat loss,4 supporting substitution of some of the fat in the
human diet with carbohydrate or protein for prevention
of weight gain. However, dietary fat is a potent stimulus
for incretin release,5 which appears to have several ben-
eﬁcial functions in energy metabolism.6 Upon digestion of
dietary fat, it is hydrolyzed to 2-monoacylglycerol and
fatty acids, which both are absorbed in the small intestine,
re-esteriﬁed and exported to the circulation with chylo-
microns. It turns out that it is the hydrolysis products that
stimulate incretin release,7–10 although recent results
suggest that fatty acids may stimulate glucagon-like pep-
tide 1 (GLP-1) release from the vascular site and not the
luminal site.11 At a dose of dietary fat reﬂecting a light
meal, e.g., 20 ml olive oil (21.6 mmol), it appears that it is
mainly the 2-monoacylglycerol moiety of the fat that is
responsible for stimulating incretin release, whereas the
fatty acid moieties may have a minor role.12 This con-
clusion was reached from studies of a C8-dietary oil, 1,3-
di-octanoyl-2-oleoyl glycerol, which upon digestion
results in formation of two molecules of a medium-chain
fatty acid, octanoic acid, and 2-oleoyl glycerol (2-OG).
Octanoic acid is a poor agonist for fatty acid receptors,13
and dietary medium-chain triglycerides are poor stimu-
lators of gut hormone release,12, 14 while 2-OG alone
readily stimulates release of incretins via activation of the
G protein-coupled receptor 119 (GPR119).12, 15, 16 Thus,
on a molar basis the C8-dietary oil has the same potency
as long-chain-triglycerides, although it provides only 61%
of the calories, i.e., for 21.6 mmol, 107 kcal versus 171
kcal.12 However, prolonged intake of octanoic acid may
have the disadvantage of stimulating the formation of
bioactive N-octanoyl-ghrelin,17, 18 which may promote
food intake. Thus, we have chosen to study another oil in
which octanoic acid is substituted by butyric acid in a
similarly structured triacylglycerol, i.e., 1,3-dibutyryl-2-
oleoyl-glycerol, henceforth designated C4-dietary oil,
which also contains even less calories (81 kcal for 21.6
mmol) on a molar basis. From mouse studies, butyric acid
is known to be able to elevate proglucagon gene expres-
sion in the intestine,19 increase the number of enter-
oendocrine L cells,20 improve vascular function and
inhibit inﬂammation, probably via inhibition of histone
deacetylases involved in epigenetic regulations.21, 22 Fur-
thermore, tributyrin/butyrate had anti-obesity and anti-
diabetic effects after prolonged feeding in mice23–25 as
also seen with microbiota-derived short-chain fatty acids;
the latter apparently exerted their anti-obesity effect via
GPR43 activation.24 Targeted delivery of another short-
chain fatty acid, propionate, had beneﬁcial effect on body
weight maintenance and adiposity in overweight adults.26
Butyric acid was reported to stimulate GLP-1 release from
murine L cells,27 although an intake of 6.53 g tributyrin
did not stimulate incretin release in humans.12
In the present study, we tested whether intake of 10.7 g
C4-dietary oil (expected to generate 7.7 g 2-OG) stimu-
lates incretin release in 13 overweight diabetic subjects.
The results were compared to those obtained after intake
of 19 g (20 ml) olive oil, which provides both long-chain
fatty acids and 2-OG (7.7 g equal to 21.6 mmol) and many
more calories (177 versus 81 kcal) or compared to a carrot
meal alone.
Material and methods
The pro-drug, C4-dietary oil, was ﬁrst tested as an
agonist as compared to the well-described agonist oleoy-
lethanolamide (OEA)28 for transiently expressed human
GPR119 in COS-7 cells, and subsequently in 13 patients
with type 2 diabetes (T2D) in a randomized, single-
blinded study. We compared the effect of C4-dietary oil
(active compound), olive oil (active comparator) on a
background of grated carrot (“placebo”) administered
orally as three different “meals” in a cross-over design.
The two oils were consumed in a shot-glass while eating
the grated carrot. The primary outcome was postprandial
plasma responses of GLP-1 measured during and 3 h after
ingestion of the different meals (assessed as incremental
area under the curve (iAUC)). Secondly, we investigated
the effects of the meals on glucose-dependent insulino-
tropic polypeptide (GIP), on insulin and glucagon release
from the pancreas, and on the appetite-regulating gut
hormones peptide YY (PYY) and cholecystokinin (CCK).
In vitro studies
GPR119 signaling
COS-7 cells were grown at 10% CO2 and 37 °C (310 K)
in Dulbecco’s modiﬁed Eagle’s medium supplemented
with GlutaMAX™ (Life Technologies Corporation,
Carlsbad, CA, USA), 10% fetal bovine serum, 180 IU/ml
penicillin and 45 µg/ml streptomycin (PenStrep) and were
transfected by the calcium phosphate precipitation
method.29 The cAMP formation was determined by the
HitHunter cAMP XS+assay (DiscoveRx, Fremont, CA,
USA).30 In brief, the transiently transfected cells were
seeded into 96-well plates (35,000 cells/well). Twenty-four
hours later, cells were washed twice with HBS buffer (20
mM HEPES, 150mM NaCl, pH 7.4) and incubated with
ligands (C4-dietary oil (Larodan, Malmø, Sweden) or OEA
(Cayman Chemicals, Ann Harbor, MI, USA)) for 30 min
at 37 °C in HBS containing 1mM isobutylmethylxanthine
phosphodiesterase inhibitor (Sigma-Aldrich, St. Louis,
MO, USA). For the in vitro experiment C4-dietary oil was
dissolved in 50% DMSO and then diluted with medium to
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the desired concentrations, having a ﬁnal concentration of
DMSO of 1%. After incubation, the medium was removed
and the cells were treated according to the protocol for
the “three reagent addition” procedure using the
HitHunter cAMP XS+assay, an enzyme fragment
complementation-based cAMP assay. The amount of
cAMP was measured as luminescence using Perkin Elmer
EnVision 2104 Multilabel Reader (Walton, MA, US).
Determinations were made in triplicate.
In vivo studies
Ethical approval
The study was conducted according to the principles of
the Helsinki Declaration II and approved by the Scientiﬁc-
Ethical Committee of the Capital Region of Denmark
(Registration Number H-3-2011-007).
Subjects
Thirteen overweight Caucasians patients (eight males,
ﬁve females) diagnosed with T2D (according to World
Health Organization criteria31) participated. All patients
were recruited from diabetes outpatient clinics in order to
reﬂect clinical reality. Patient characteristics are listed in
Table 1. All participants had negative tests of islet cell
auto-antibodies and glutamate decarboxylase 65 auto-
antibodies. Exclusion criteria included kidney disease with
serum creatinine >130 µM and/or albuminuria, liver dis-
ease with plasma alanine transaminase >twice the upper
limit of the normal range, diabetic neuropathy, pro-
liferative retinopathy, anemia, treatment with insulin,
GLP-1 receptor agonist and/or dipeptidyl peptidase 4
(DPP-4) inhibitor and inability to pause medication for at
least 10 h. The subjects had a ‘low’ HbA1c but they
paused their antidiabetic medication (biguanide or sulfo-
nylurea) 7 days prior to each test day and therefore pre-
sent with a fairly high fasting blood glucose level. All
subjects agreed to participate by signing an informed
consent after receiving oral and written information prior
to procedures. The participants were identiﬁed by a study
protocol identiﬁcation number.
Study design
The study was designed as a randomized, single-blinded
cross-over study. It was blinded for the patients and
analyst but it was not possible to blind it for the staff
handling the different oils. The subjects were studied in a
recumbent position after an overnight (10 h) fast includ-
ing water, medication and tobacco abstinence. A cannula
was inserted into a cubital vein. The cannulated arm was
wrapped in a heating pad throughout the experiment for
collection of arterialized blood samples. On three different
days and in random order the participants received the
different test meals, consisting of 200 g grated carrot and
1.0 g acetaminophen dissolved in 40ml water plus a shot
glass of either (a) 19 g of olive oil, or (b) 10.7 g of diet oil,
or (c) no addition. Acetaminophen was added in order to
measure gastric emptying rate. Two-hundred grams car-
rot was used as vehicle since it had no measurable effect
on incretin hormone concentrations in peripheral
plasma.12 There were 2–10 days between the different
study days in order to avoid too much baseline variation.
Theoretically, both oil “meals” would result in formation
of 7.7 g 2-OG during digestion. The caloric content of the
oils was 171 kcal (olive oil) and 81 kcal (C4-dietary oil),
respectively, calculated on the basis of the amount of ATP
generated from total oxidation of the two oils, and the
notion that dietary fat contains 9 kcal/g. As shown in the
ﬁgures arterialized blood was drawn at speciﬁc timepoints
after ingestion of the meal and dispensed into chilled
tubes containing EDTA plus aprotinin (500 KIU/ml
blood; Trasylol®, Bayer Corp., Leverkusen, Germany) and a
speciﬁc DPP-4 inhibitor (valine-pyrrolidide (0.01 mM); a
gift from Novo Nordisk, Bagsværd, Denmark) for analysis
of glucagon, GIP, GLP-1, PYY, CCK and triglycerides. For
insulin and C-peptide analyses, blood was sampled into
chilled tubes containing heparin. All tubes were kept on
ice before and after blood sampling. They were cen-
trifuged for 20 min at 1.500g and 4 °C. Plasma for gluca-
gon, GLP-1, GIP, PYY, CCK and triglyceride analyses was
stored at −20 °C and plasma for insulin and C-peptide
analyses was stored at −80 °C until analysis. For analysis
of acetaminophen, blood was distributed into dry vials
and left to coagulate for 20 min at room temperature
before centrifugation and handling as described below.
For bedside measurement of plasma glucose (PG), blood
was collected in ﬂuoride tubes and centrifuged (7.400g)
immediately for 2 min at room temperature.
Solutions
Olive oil (Frantoio 100% italiano, non ﬁltrato, olio extra
vergine di oliva) was from the manufacturer “Rocchi”
Table 1 Patient characteristics
Male/female 8/5
Age (years) 65 (47–75)
Body weight (kg) 91.9 ± 16.5
BMI (kg/m2) 30.0 ± 4.3
Fasting PG (mM) 9.0 ± 3.6
HbA1c (%) 6.9 ± 1.3
Fam. history of diabetes 8
Years of diabetes 4 (0.5–11)
Data are numbers (gender) or mean values ± standard deviation SD or with
range in parentheses (age and years of diabetes)
BMI body mass index, FPG fasting plasma glucose, HbA1c glycated hemoglobin
A1c
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(Oleiﬁcio R.MSant’Alessio Lucca, Italy). C4-dietary oil
(1,3-dibutyryl 2-oleoyl glycerol of> 97% purity, with
impurities being mainly 1,2-dibutyryl 3-oleoyl glycerol)
was from Larodan (Malmø, Sweden). 1,3-dibutyryl
2-oleoyl glycerol is a natural constituent of milk fat.32
Analyses
Plasma samples were assayed for total GLP-1 immu-
noreactivity, as previously described,33 using antiserum
no. 89390, which is speciﬁc for the C-terminal of the
GLP-1 molecule. Intact, biologically active GIP was
measured using antiserum no. 98171 as previously
described.34 PYY(3–36) was measured using a commer-
cially available radioimmunoassay kit from Millipore
(catalog no. PYY-67HK; Billerica, MA, USA). The
detection limit was 5 pM. The assay shows no cross-
reaction with PYY(1–36) up to 250 pM. All quality
controls were within prespeciﬁed limits. The con-
centrations of PG were measured bedside by the glucose
oxidase method using a glucose analyzer (YSI model
2300 STAT plus analyzer; Yellow Springs Instrument
Inc., Yellow Springs, OH, USA). Plasma C-peptide and
insulin concentrations were measured using two-sided,
electrochemiluminescense immunoassays (Roche/Hita-
chi modular analytics; Roche Diagnostic GmbH, Man-
nheim, Germany). The detection limit was less than
2 pM for both assays, and intra-assay coefﬁcients of
variation were 4.6% for the C-peptide assay and 1.9% for
the insulin assay.35 The glucagon assay is directed
against the C terminal of the glucagon molecule (anti-
body code no. 4305) and therefore measures glucagon of
mainly pancreatic origin.36–38 CCK was measured as
described earlier using antiserum no. 92128, which binds
all bioactive forms of CCK and displays no cross-
reactivity with gastrin.39 Triglycerides were measured
using an enzymatic kit from Sigma-Aldrich (catalog no.
TR0100; Saint Louis, MO, USA) with a modiﬁed proto-
col using 2 µl of plasma. Enzymatic reactions were per-
formed in duplicates and measured in 96-well plates at
550 nm. Triglyceride concentrations were calculated
according to the protocol. The working range was from
0.7 mM to 11.3 mM deﬁned by a recovery of at least 80%
and a coefﬁcient of variation of <10%. Serum samples
were assayed for acetaminophen using Vitros Chemistry
Systems (Otho Clinical Diagnostics, Johnson & Johnson,
Buckinghamshire, UK).
Statistical analyses and calculations
All results are expressed as means ± SEM unless
otherwise mentioned. Statistical analysis was performed
using Prism Graphpad 4 software (GraphPad Software,
Inc., CA, USA). Repeated measurements ANOVA was
followed by Tukey post hoc test. Area under curve (AUC)
values were calculated using the trapezoidal rule and are
presented as the incremental (area below baseline sub-
tracted) AUC (iAUC) values if nothing else is stated in
order to adjust for different baseline values. Furthermore,
we analyzed differences in individual time points using
paired t tests. The acetaminophen absorption test was
used to determine gastric emptying rates40 calculated
from tAUC.
Results
In vitro data
The study on the COS-7 cells shows as expected no
effect of C4-dietary oil in vitro (Fig. 1), in contrast to the
potent stimulation by OEA with a half maximal effective
concentration (EC50) of 1.2× 10
−7 M.
In vivo data
Fourteen participants were initially recruited of whom
one did not complete the study. This participant was
excluded the 1st day of the study, because he was unable
to eat 200 g carrot and vomited during ingestion of
C4-dietary oil.
GLP-1, GIP and PYY
Baseline plasma values for GLP-1 (olive oil: 10.0± 0.9
pM, C4-dietary oil: 8.1± 0.5 pM and carrot: 8.7± 0.6 pM.
P= 0.01) and GIP (olive oil: 12.5± 2.1 pM, C4-dietary oil:
7.3± 1.2 pM, carrot: 8.6± 1.0 pM. P= 0.02), respectively,
differed slightly on the different study days, while there
was no difference for PYY (Table 2). Ingestion of both
olive oil and C4-dietary oil in combination with carrot
elicited greater GLP-1 (olive oil: 645± 194 pM×min, C4-
dietary oil: 702± 97 pM×min, carrot: 7± 103 pM×min.
P= 0.002) and GIP (olive oil: 4338± 764 pM×min,
C4-dietary oil: 2894± 601 pM×min, carrot: 266± 234
pM×min. P< 0.0001) responses compared to the meal
consisting of only carrot, and there were no differences in
Fig. 1 In vitro. C4-Dietary-oil does not by itself activates GPR119
transiently expressed in COS-7-cells. Formation of cAMP was
measured after stimulating GPR119-expressing COS-7 cells with
oleoylethanolamide (OEA) and C4-dietary oil. The response is shown
as percentage between full stimulation with OEA (100%) and no
stimulation (0%) (n = 3)
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iAUC between olive oil-day and C4-dietary oil-day
(Table 3). The peak value for GLP-1 was not different
between the oil-days, whereas the peak value for GIP was
higher for the olive oil-day than for the C4-dietary oil-day
(olive oil: 68.85± 9.24 pM, C4-dietary oil: 38.92± 7.10
pM, carrot: 19.54± 2.46 pM. P< 0.0001 (Table 4)). iAUC
and peak values for PYY were similar on the 3 days
(Fig. 2, Table 3).
Table 2 Baseline values
Olive oil (a) C4-Dietary oil (b) Carrot (c) P value
GLP-1 10.0 ± 0.9 8.1 ± 0.5 8.7 ± 0.6 0.01a>b
GIP 12.5 ± 2.1 7.3 ± 1.2 8.6 ± 1.0 0.02a>b
PYY 63.1 ± 7.1 52.7 ± 5.5 58.1 ± 7.9 0.51
Glucose 8.9 ± 0.9 8.8 ± 1.0 9.2 ± 1.1 0.28
C-peptide 1,302 ± 79 1,270 ± 99 1,412 ± 86 0.11
Insulin 123 ± 15 113 ± 12 146 ± 16 0.05
Glucagon 12.7 ± 1.5 12.1 ± 1.3 12.6 ± 1.5 0.80
CCK 0.8 ± 0.2 1.0 ± 0.3 0.8 ± 0.2 0.34
Triglycerides 1.3 ± 0.2 1.3 ± 0.2 1.2 ± 0.2 0.86
Data are mean values ± SEM. All values in pM except glucose in mM. P values were calculated using repeated measurement ANOVA. P values ≤ 0.05 are considered
statistically signiﬁcant. Statistical signiﬁcant differences between the three treatments are shown using the letters a, b and c, referring to the treatments
CCK cholecystokinin, GIP glucose-dependent insulinotropic polypeptide (intact), GLP-1 glucagon-like peptide-1 (total), PYY peptide YY
Table 3 Area under curve (AUC)
Olive oil (a) C4-Dietary oil (b) Carrot (c) P value
GLP-1 iAUC 645 ± 194 702 ± 97 7 ± 103 0.002a>c, b>c
GLP-1 tAUC 2,580 ± 204 2,247 ± 115 1,698 ± 115 0.0002a>c, b>c
GIP iAUC 4,338 ± 764 2,894 ± 601 266 ± 234 <0.0001a>c, b>c
GIP tAUC 6,891 ± 1068 4,300 ± 765 2,055 ± 243 <0.0001a>b, a>c, b>c
PYY iAUC 855 ± 1,009 1,402 ± 581 −612 ± 628 0.21
PYY tAUC 13,110 ± 1,526 11,430 ± 1,344 10,650 ± 1,269 0.02a>c
Glucose iAUC 61 ± 26 172 ± 77 148. ± 38 0.23
Glucose tAUC 1,791 ± 197 1,837 ± 213 1,927 ± 225 0.04c>a
C-peptide iAUC 66,050 ± 10,800 66,310 ± 9,302 49,130 ± 10,800 0.08
C-peptide tAUC 320,100 ± 20,830 314,000 ± 25,310 324,400 ± 24,840 0.78
Insulin iAUC 8,438 ± 2,222 10,690 ± 1,671 4,901 ± 1,883 0.02b>c
Insulin tAUC 32,430 ± 2,220 32,580 ± 3,451 33,430 ± 3,378 0.92
Glucagon iAUC 17 ± 104 420 ± 95 18 ± 83 0.005b>a, b>c
Glucagon tAUC 2,513 ± 278 2,556 ± 350 2,292 ± 343 0.11
CCK iAUC 103 ± 34 33 ± 37 −11 ± 22 < 0.01a>c
CCK tAUC 252 ± 29 229 ± 27 151 ± 19 0.001a>c, b>c
Triglycerides iAUC 12.0 ± 6.8 −4.4 ± 3.9 −7.3 ± 6.0 0.013a>b, a>c
Triglycerides tAUC 240 ± 39 226 ± 27 210 ± 28 0.48
Acetaminophen tAUC 11.7 ± 1.0 13.4 ± 1.2 14.0 ± 1.2 0.02a<c
Data are mean values ± SEM. All values in pM ×min except glucose and triglycerides in mM ×min and acetaminophen in µM ×min. P values are calculated using
repeated measurement ANOVA. P values ≤ 0.05 are considered statistically signiﬁcant. Statistically signiﬁcant differences between the three treatments are shown
using the letters a, b and c, referring to the treatments
CCK cholecystokinin, GIP glucose-dependent insulinotropic polypeptide (intact), GLP-1 glucagon-like peptide-1 (total), iAUC incremental area under curve, PYY peptide
YY, tAUC total area under curve
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Glucose, insulin, C-peptide and glucagon
There were no differences in baseline concentrations or
iAUCs for C-peptide or glucose responses, respectively
(Fig. 2, Table 3). Insulin iAUC was greater with C4-dietary
oil compared to carrot alone (olive oil: 8438± 2222 pM×
min, C4-dietary oil: 10,690± 1671 pM×min, carrot:
4901± 1883 pM×min. P= 0.02 (Table 3)). Baseline
concentrations of glucagon were similar during the three
study days. A very slight but higher glucagon response
was observed for C4-dietary oil compared to olive oil and
grated carrot (olive oil: 17± 104 pM×min, C4-dietary oil:
420± 95 pM×min, carrot: 18± 83 pM×min. P= 0.005
(Table 3)).
CCK and triglycerides
No differences in baseline concentrations were observed
between the three experimental days for CCK or trigly-
cerides, respectively (Table 2). Olive oil elicited a greater
rise in triglyceride concentrations whereas C4-dietary oil
and carrots were without effect (olive oil: 12.0± 6.8
mM×min, C4-dietary oil: −4.4± 3.9 mM×min, carrot:
−7.3± 6.0 mM×min. P= 0.013 (Table 3, Fig. 2)). A
higher CCK response was seen following olive oil com-
pared to grated carrot (olive oil: 103± 34 pM×min, C4-
dietary oil: 33± 37 pM×min, carrot: −4± 22 pM×min.
P< 0.01 (Table 3, Fig. 2)). There was no difference for
iAUCCCK between olive oil and C4-dietary oil, and both
elicited peak values that were higher than the control
meal with only carrot (olive oil: 2.71± 0.36 pM,
C4-dietary oil: 2.73± 0.40 pM, carrot: 1.37± 0.16 pM.
P= 0.0040 (Fig. 2, Table 3, Table 4)).
Gastric emptying rate
Gastric emptying rate estimated as the tAUC for acet-
aminophen, was lower with olive oil compared to the
carrot meal (olive oil: 11.7± 1.0 µM×min, C4-dietary oil:
13.4± 1.2 µM×min, carrot: 14.0± 1.2 µM×min. P=
0.02 (Table 3)).
Discussion
Our in vitro data demonstrate that C4-dietary oil by
itself cannot activate GPR119, in accordance with the
Table 4 Peak time (pt) and value (pv)
Olive oil (a) C4-Dietary oil (b) Carrot (c) P value
GLP-1 pt 55.38 ± 8.04 57.31 ± 5.68 38.08 ± 11.98 0.27
GLP-1 pv 20.77 ± 1.86 18.77 ± 1.59 13.69 ± 1.33 0.012a>c
GIP pt 62.31 ± 5.30 56.92 ± 7.17 43.85 ± 7.08 0.15
GIP pv 68.85 ± 9.24 38.92 ± 7.10 19.54 ± 2.46 < 0.0001a>b>c
PYY pt 56.92 ± 11.79 97.31 ± 13.05 40.38 ± 9.24 0.0061b>c
PYY pv 93.77 ± 10.77 82.92 ± 12.45 79.08 ± 9.72 0.59
Glucose pt 54.23 ± 8.49 63.08 ± 10.93 49.62 ± 6.06 0.61
Glucose pv 9.89 ± 1.05 10.28 ± 1.13 10.84 ± 1.22 0.0090a>c
C-peptide pt 76.92 ± 7.44 85.77 ± 10.54 77.69 ± 10.49 0.51
C-peptide pv 1,918 ± 134.1 1,867 ± 154.0 1,883 ± 152.6 0.86
Insulin pt 60.77 ± 6.09 55.38 ± 5.90 42.31 ± 9.75 0.16
Insulin pv 246.6 ± 20.17 234.2 ± 24.68 232.7 ± 24.14 0.76
Glucagon pt 25.38 ± 4.62 36.92 ± 5.68 22.31 ± 3.03 0.12
Glucagon pv 17.08 ± 2.01 18.31 ± 2.60 16.62 ± 2.07 0.19
CCK pt 55.77 ± 14.38 36.15 ± 6.15 25.77 ± 5.48 0.096
CCK pv 2.71 ± 0.36 2.73 ± 0.40 1.37 ± 0.16 0.0040a+b>c
Triglycerides pt 154.6 ± 9.52 110.8 ± 21.32 71.54 ± 17.50 0.0093a>c
Triglycerides pv 1.54 ± 0.23 1.37 ± 0.16 1.27 ± 0.18 0.19
Acetaminophen pt 44.23 ± 12.30 43.85 ± 10.27 38.08 ± 5.98 0.69
Acetaminophen pv 0.11 ± 0.01 0.12 ± 0.01 0.13 ± 0.01 0.681
Data are mean values ± SEM. All peak times in minutes, all peak values in pM except triglycerides and glucose in mM and acetaminophen in µM. P values are
calculated using repeated measurement ANOVA. P-values ≤0.05 are considered statistically signiﬁcant. Statistical signiﬁcant difference between the three treatments
is shown using the letters a, b and c, referring to the treatments
CCK cholecystokinin, GIP glucose-dependent insulinotropic polypeptide (intact), GLP-1 glucagon-like peptide-1 (total), iAUC incremental area under curve, PYY peptide
YY, tAUC total area under curve
Mandøe et al. Nutrition and Diabetes             (2018) 8:2 Page 6 of 10
Nutrition and Diabetes
0 30 60 90 120 150 180
0
5
10
15
20
Time (min)
G
LP
-1
(p
m
ol
/L
)
0 30 60 90 120 150 180
0
10
20
30
40
50
60
70
Time (min)
G
IP
(p
m
ol
/L
)
0 30 60 90 120 150 180
7
8
9
10
11
12
Time (min)
P-
G
lu
co
se
(m
m
ol
/L
)
0 30 60 90 120 150 180
1000
1500
2000
C
-p
ep
tid
e
(p
m
ol
/L
)
Time (min)
0 30 60 90 120 150 180
7
9
11
13
15
17
19
21
Time (min)
G
lu
ca
go
n
(p
m
ol
/L
)
0 30 60 90 120 150 180
25
50
75
100
PY
Y
(p
m
ol
/L
)
Time (min)
0 30 60 90 120 150 180
0.5
1.5
2.5
C
C
K
(p
m
ol
/L
)
Time (min)
0 30 60 90 120 150 180
1.5
2.0
Time (min)
Tr
ig
ly
ce
rid
e
(m
m
ol
/L
)
Fig. 2 Time courses for plasma GLP-1, GIP, plasma glucose, glucagon, c-peptide, triglycerides, PYY and CCK following ingestion of olive oil
and carrot (squares), C4-dietary oil and carrot (circles) and carrot alone (crosses). The three time points prior to ingestion was used in order to
determine baseline and are only included as one point-value
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observation that a hydroxyl group in the lipid molecule is
required for agonist activity on GPR119.15 This indicates
that C4-dietary oil, like other triglycerides, must be
hydrolyzed before it can activate nutrient sensors.41, 42
Several different lipids (lysophopholipids, acylamides,
2-monoacylglycerols) can act as agonists for GPR119
in vitro.15, 43 We have shown that 2-OG stimulates
GPR119 not only in vitro, but probably also in vivo where
direct administration of 2 g 2-OG in the intestine of
healthy subjects resulted in an increase in plasma GLP-1
within 25min after administration.16 Oleic acid in an
amount corresponding to that present in 2 g 2-OG did not
stimulate GLP-1 release, suggesting that the meal-related
formation of 2-monoacylglycerols acting on GPR119
during fat ingestion is indeed responsible for a signiﬁcant
part of the GLP-1 response. Recently, we have shown that
compared to 20 ml (19 g) olive oil, an equimolar amount
of 1,3-dioctanoyl 2-oleoyl glycerol (13.15 g, 21.6 mmol)
was just as effective with respect to GLP-1 release in
humans, suggesting that the stimulating factor in the
consumed olive oil may be mainly 2-OG acting on
GPR119.12 Studies of a mouse model involving self-
administration of fat emulsions also demonstrated the
mice can sense 2-OG in the gastrointestinal system
probably via GPR119 activation.44
The present in vivo study was designed to characterize
the effect of C4-dietary oil on incretin hormone secretion
compared with equimolar amounts of olive oil and with
grated carrots, respectively, in overweight patients with
T2D. By examining the same individuals in a cross-over
design inter-individual variation was minimized. Patients
were naturally more well treated due to exclusion criteria,
but they were recruited from diabetes outpatient clinics in
order to reﬂect reality well. Although fatty acids generated
from the digestion of olive oil may stimulate incretin
release via GPR40 and GPR1207, 8 or other mechanisms,9
they are also rapidly absorbed together with 2-
monoacylglycerol and subsequently re-esteriﬁed. Appar-
ently, at a dose of 20 ml olive oil to healthy human sub-
jects, the long-chain fatty acid moiety of olive oil seems to
play a minor role in GLP-1 release, while it seems to have
an additive effect together with 2-OG on GIP release and
be of major responsibility for CCK release.12 In the pre-
sent study, C4-dietary oil also gave the same GLP-1
response as olive oil, further supporting the GLP-1-
releasing action of 2-OG, while the C4 fatty acid (buty-
rate) seems to have no effect, as judged from the ﬁnding
that an oral intake of an equimolar amount of tributyrin
did not stimulate GLP-1 release.12 The iAUCs for GIP on
the olive oil-day and the C4-dietary oil day were not dif-
ferent although the peak value for GIP was clearly higher
on the olive oil-day. In our previous study, we found that
the GIP response to olive oil can be explained by a
combined stimulatory effect of both 2-OG and oleic
acid,12 and the present data tend to support this conclu-
sion. Since the incretin responses to 19 g of olive oil (171
kcal) and only 10.7 g of C4-dietary oil (81 kcal) were
similar, this indicates that C4-dietary oil, per unit of
energy content, is more effective than olive oil in releasing
GLP-1 and probably also GIP.
Neither olive oil nor C4-dietary oil had effects on iAUC
for PYY, although our previous study demonstrated a
clear PYY-stimulating effect of equimolar doses of both
C8-dietary oil and olive oil in healthy subjects.12 Whether
this difference in PYY responses is due to testing the oils
on overweight patients with T2D as compared to the
previous study, where they were tested on healthy subjects
is at present not clear. However, Fernandez-Garcia et al.45
has shown that in morbidly obese subjects, both insulin
resistance and abnormal glucose metabolism impair GLP-
1 and PYY responses to a 60 g fat load. Also, the 2-OG
receptor GPR119 has been reported to be involved in
stimulating PPY release.46
In the present study, both oils stimulated CCK release
with olive oil being more efﬁcacious than C4-dietary oil,
while in our previous study C8-dietary oil and tributyrin
did not stimulate a CCK response.12 One explanation for
these differences in CCK responses between the C8-
dietary oil study12 and the present C4-dietary oil study
may possibly be related to the rate of gastric metabolism
of these two structured triglycerides. Due to the short-
chain fatty acids in C4-dietary oil it may have been
metabolized more rapidly in the stomach by gastric lipase
than C8-dietary oil. This would result in the generation of
2-OG having longer time to undergo spontaneous acyl
migration47 before entering the intestine, thereby result-
ing in formation of 1-oleoyl glycerol, which is substrate
for hydrolysis by both gastric lipase and pancreatic
lipase.48 This would result in a larger proportion of free
oleic acid generated from C4-dietary oil than from C8-
dietary oil. Long-chain fatty acids are known to stimulate
CCK release.49, 50
GLP-1 secretion may be stimulated by CCK.51 However,
in our study we saw a GLP-1 release in the C4-dietary oil
group after 75 min when CCK levels were low. In earlier
studies, we did not observe increased GLP-1 secretion
after CCK administration, however,52 so in support of our
earlier studies12, 16 it seems that a GLP-1 release induced
by 2-OG can be elicited without involving CCK release.
Administration of all three meals was followed by an
increase in the PG (no difference among meals) reﬂecting
digestion of the carbohydrates in carrots.12 There was a
tendency that the oil meals elicited higher C-peptide
responses (Fig. 2). However, the greater increase in both
GLP-1 and GIP following ingestion of oils compared to
carrots was not sufﬁcient to inﬂuence insulin secretion in
these experiments. GLP-1 is known to increase insulin
secretion in a dose-dependent manner.53–55 In a previous
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study, GLP-1 infusions resulting in peripheral plasma GLP-
1 concentrations of ∼50 pM stimulated insulin secretion at
fasting glucose levels, but in the current study, the increase
of GLP-1 from 8 to 15 pM might be too small to inﬂuence
insulin secretion signiﬁcantly.53 We know from previous
studies55 that in order to demonstrate the insulinotropic
effect of GLP-1 and GIP at fasting PG concentrations, it is
necessary to clamp PG most thoroughly. That was unfor-
tunately not done in the current study. We also know that
portal insulin levels can be up to six times higher than the
peripheral levels given that the ﬂow of the splanchnic cir-
culation is one third of the systemic and that the hepatic
insulin extraction is 50%. Therefore, we cannot say that the
incretin release was insufﬁcient in this study. On the
contrary, these data suggest an effect due to the relatively
low glucose values on oil days.
In animal studies in which GPR119 agonists were
administered in high doses without inﬂuencing glucose
concentrations,56 stimulation of the GPR119 also had no
insulinotropic activity at lower glucose concentrations. In
addition, the lack of acute effect on insulin secretion in
our study may be due to the decreased sensitivity of the
beta cells to incretin hormones in T2D, as shown by
Højberg et al.57 In that study, no increase in insulin
release following intravenous infusion of GLP-1 and GIP
(resulting in physiological plasma concentrations),
respectively, was observed.
Gastric emptying might have inﬂuenced the results
observed in this study. Our results show that olive oil
inhibited gastric emptying. In our previous study,12 we
saw no clear effect of the same dose of 20 ml olive oil on
gastric emptying in healthy subjects. Gastric emptying
rate was evaluated using the acetaminophen absorption
test. The test is an indirect assessment of gastric empty-
ing, and it is well validated against scintigraphic methods
considered the gold standard for measurements of gastric
emptying.58, 59 In the present study, there were no dif-
ferences in gastric emptying between C4-dietary oil and
carrot alone, suggesting that fatty acids from olive oil may
contribute to the effect on gastric emptying in these
overweight patients with T2D.
Recently, it has been shown that diabetic mice lacking
the short-chain receptors, GPR41 and GPR43, have
increased insulin secretion and improved glucose toler-
ance60 thereby questioning the beneﬁcial metabolic role
of dietary short chain fatty acids via this pathway,
although prolonged oral intake of butyrate in diet-induced
obese mice resulted in increased insulin sensitivity and
increased energy expenditure.23 Anyhow, both C4-dietary
oil and C8-dietary oil increased GLP-1 release just as
efﬁcaciously as equimolar amounts of olive oil, which
provided more calories. Further studies evaluating
chronic administration of C4-dietary oil or C8-dietary oil
for a longer period should therefore be carried out, since
beta cell sensitivity to incretin hormones may improve
during anti-diabetic therapy.49
In conclusion, our study suggests that postprandial
GLP-1 and GIP responses in overweight patients with
T2D may be augmented by GPR119 activation. C4-dietary
oil had on a molar basis the same activity as olive oil.
However, if one calculates by unit of energy, C4-dietary
oil may be more potent as incretin releaser than olive oil
and could possibly be useful for some dietary products.
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